FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)
This is a discussion on FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine) within the FDA News forum, part of the Industry News and Updates category; [01-29-2010] The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals and patients about a rare, ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
02-06-2010, 07:38 AM
|
|||
|
|||
FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)
[01-29-2010] The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals and patients about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine).
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (nataliz | industry_news | FDA News | 0 | 02-05-2010 12:52 PM |
| FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine) | industry_news | FDA News | 0 | 01-29-2010 02:36 PM |
| Early Communication About Safety of Lantus (insulin glargine) | industry_news | FDA News | 0 | 07-01-2009 11:14 AM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |